In addition, ATIC, HPRT1, ASNS, SULT1A2, and HAL may represent attractive therapeutic targets for HER2-positive breast cancer, and require further validation studies, especially considering that treatment with specific inhibitors may alter the expression of these metabolic genes. Here, ERBB2 is linked to breast cancer.